The Brazilian National Health Supervision Agency announced on the 9th that it has approved the Butantan Institute to conduct clinical trials of its COVID-19 vaccine ButanVac. It is expected that 6,000 volunteers aged 18 and above will participate in the Phase I and Phase II clinical trials. The vaccine requires two doses with an interval of 28 days.
The Butantan Institute applied to Brazil’s National Health Supervision Agency for clinical trials of ButanVac on March 26. Production of the vaccine began in April, and 18 million doses are expected to be produced in June.
The vector virus used in this vaccine is Newcastle Disease Virus. Chicken Newcastle disease is a disease that only infects birds. Chicken Newcastle disease virus can replicate in large numbers in egg embryos, but it does not cause symptoms in humans. According to Brazilian media reports, the raw materials for the production of this vaccine can be obtained locally and do not rely on imports.
The latest data released by the Brazilian Ministry of Health on the 9th showed that there were 85,748 new confirmed cases of COVID-19 in Brazil compared with the previous day, with a total of 17,122,877 confirmed cases; 2723 new deaths and a total of 47,515 deaths; a total of 15,596,816 cases were cured.
According to the combined statistics of the Brazilian mainstream media based on the data released by the state health departments, as of 20:00 on the 9th, 51,846,929 people across the country have received the first dose of COVID-19 vaccine, accounting for 24.48% of the total population, and 23,418,325 people have received the second dose of vaccine. , Accounting for 11.06% of the total population.
0 Comments